Abstract:Long non-coding RNAs (lncRNAs) have been implicated in cancer progression and drug resistance development. Moreover, there is evidence that lncRNA HOX transcript antisense intergenic RNA (HOTAIR) is involved in colorectal cancer (CRC) progression. The present study aimed to examine the functional role of lncRNA HOTAIR in conferring radiotherapy resistance in CRC cells, as well as the underlying mechanism. The relative expression levels of HOTAIR were examined in 70 pairs of CRC tumor and para-cancerous tissues, as well as in radiosensitive and radioresistant samples. The correlations between HOTAIR expression levels and clinical features of patients with CRC were assessed using the Chi-square test. Functional assays such as cell proliferation, colony formation and apoptosis assays were conducted to determine the radiosensitivity in CRC cells with HOTAIR silencing after treatment with different doses of radiation. RNA pull-down assay and fluorescence in situ hybridization (FISH) were used to determine the interaction between HOTAIR and DNA damage response mediator ataxia-telangiectasia mutated- and Rad3-related (ATR). HOTAIR was significantly upregulated in CRC tumor tissues, especially in radioresistant tumor samples. The elevated expression of HOTAIR was correlated with more advanced histological grades, distance metastasis and the poor prognosis in patients with CRC. Silencing HOTAIR suppressed the proliferation and promoted apoptosis and radiosensitivity in CRC cells. HOTAIR knockdown also inhibited the tumorigenesis of CRC cells and enhanced the sensitivity to radiotherapy in a mouse xenograft model. Moreover, the data showed that HOTAIR could interact with ATR to regulate the DNA damage repair signaling pathway. Silencing HOTAIR impaired the ATR-ATR interacting protein (ATRIP) complex and signaling in cell cycle progression. Collectively, the present results indicate that lncRNA HOTAIR facilitates the DNA damage response pathway and promotes radioresistance in CRC cells by targeting ATR.

The role of HOTAIR in the modulation of resistance to anticancer therapy

LncRNA-HOTAIR Activates Autophagy and Promotes the Imatinib Resistance of Gastrointestinal Stromal Tumor Cells Through a Mechanism Involving the Mir-130A/ ATG2B Pathway

Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance

HOTAIR to Induce EGFR-TKIs Resistance in Non-Small Cell Lung Cancer Via Epithelial-Mesenchymal Transition.

Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases

Dampening HOTAIR sensitizes the gastric cancer cells to oxaliplatin through miR-195-5p and ABCG2 pathway

Large Intervening Non-Coding RNA HOTAIR Is an Indicator of Poor Prognosis and a Therapeutic Target in Human Cancers

LncRNA HOTAIR promotes DNA damage repair and radioresistance by targeting ATR in colorectal cancer

Long Non-Coding RNA HOTAIR Enhances Radioresistance in MDA-MB231 Breast Cancer Cells

Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells

HOTAIR: a key regulator in gynecologic cancers

HOTAIR Promotes Gefitinib Resistance Through Modification of EZH2 and Silencing P16 and P21 in Non-Small Cell Lung Cancer

HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer

HOTAIR/miR-1277-5p/ZEB1 Axis Mediates Hypoxia-Induced Oxaliplatin Resistance Via Regulating Epithelial-Mesenchymal Transition in Colorectal Cancer

LncRNA HOTAIR Contributes to Sorafenib Resistance Through Suppressing Mir-217 in Hepatic Carcinoma

Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2

LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer

Long non-coding RNA HOTAIR: A biomarker and therapeutic target in urological tumors

HOTAIR mediates cisplatin resistance in nasopharyngeal carcinoma by regulating miR-106a-5p/SOX4 axis

The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells